Raymond James Financial
AVIR icon

Raymond James Financial’s Atea Pharmaceuticals AVIR Stock Holding History

Raymond James Financial’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400
Closed -$1.44K – 5102
2025
Q2 		$1.44K Buy
+400
New +$1.19K ﹤0.01% 6491

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial's AVIR Position: Q3 2025 in Review

Raymond James Financial sold out of Atea Pharmaceuticals (AVIR) in Q3 2025, closing a stake of 400 shares — an estimated $1.44K sold.

Raymond James Financial first reported a position in AVIR in Q2 2025 and held it in 1 quarter. The position peaked at $1.44K in Q2 2025. 115 funds tracked by Wall St. Rank hold AVIR as of Q3 2025.

  • Raymond James Financial reported no remaining Atea Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 400 Atea Pharmaceuticals shares in Q3 2025, an estimated $1.44K.
  • Raymond James Financial first reported a position in Atea Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Atea Pharmaceuticals position peaked at $1.44K in Q2 2025.
  • 115 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.